Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures. Component of the CYFIP1-EIF4E-FMR1 complex which binds to the mRNA cap and mediates translational repression. In the CYFIP1-EIF4E-FMR1 complex this subunit mediates the binding to the mRNA cap.
eIF4E in MCF-7 Human Cell Line. eIF4E was detected in immersion fixed MCF-7 human breast cancer cell line using 10 ug/ml Human/Mouse/Rat eIF4E Monoclonal Antibody for 3 hours at room temperature. Cells were stained with the NorthernLights 557-conjugated Anti-Mouse IgG Secondary Antibody (red) and counterstained with DAPI (blue).
Detection of Human/Mouse/Rat eIF4E by Western Blot. Western blot shows lysates of MCF-7 human breast cancer cell line, Balb/3T3 mouse embryonic fibroblast cell line, and PC-12 rat adrenal pheochromocytoma cell line. PVDF membrane was probed with 0.1 ug/ml of Human/Mouse/Rat eIF4E Monoclonal Antibody followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody. A specific band was detected for eIF4E at approximately 25 kD (as indicated). This experiment was conducted under reducing conditions.
Requested From: United States
Date Requested: 10/21/2016